Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT03846310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03846310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2019
Completion date
November 18, 2024
Enrollment
77 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, non small cell lung cancer metastatic, nonsquamous nonsmall cell neoplasm of lung, sensitizing egfr gene mutation